Quantcast

Latest hepatitis C Stories

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-06-13 08:23:52

NEW YORK, June 13, 2014 /PRNewswire/ -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is a biopharmaceutical company that is engaged in the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, the company is primarily focused on developing commercially competitive, short duration combination therapies for the treatment of chronic hepatitis C virus (HCV) that are once-daily and ribavirin-free. Hepatitis C is...

2014-06-03 12:39:28

CAMBRIDGE, Mass., June 3, 2014 /PRNewswire/ -- The National Institute of Health has awarded a Phase I Small Business Innovation Research (SBIR) grant to Daktari Diagnostics for a point-of-care hepatitis C diagnostic system. Daktari, which commercializes diagnostic platforms to meet the health care needs in Africa, Asia, and resource-limited settings worldwide, will use the grant funding to continue development of the Daktari HCV assay, which runs on the same point-of-care platform...

2014-05-29 08:29:27

SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection. Benitec Biopharma's CEO and Managing Director, Peter French said, "The commencement of this clinical trial of TT-034 represents a landmark in the Company's...

2014-05-28 23:11:06

One of the nation’s leading specialty pharmacies, BioPlus, announces the hiring of Robert Jones, Jr. as a Regional Clinical Liaison to better support prescriber offices and patients in North Carolina, South Carolina, and Georgia. Altamonte Springs, FL (PRWEB) May 28, 2014 BioPlus Specialty Pharmacy, one of the nation’s leading specialty pharmacies, welcomes Robert (Bobby) Jones, Jr. to the company. He has been hired as a new Regional Clinical Liaison focused on the area of hepatitis C...

2014-05-27 23:02:43

RxSteward, BioPlus’ cost-saving intervention program, provides significant cost savings to payers, according to data from hepatitis C patients presented at Armada’s 2014 Annual Specialty Pharmacy Summit. Altamonte Springs, FL (PRWEB) May 27, 2014 BioPlus Specialty Pharmacy (BioPlus), one of the nation’s largest specialty pharmacies specializing in hepatitis C, presented at an educational panel during Armada’s 2014 Annual Specialty Pharmacy Summit & Expo. BioPlus’...

2014-05-22 08:29:21

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL, May 22, 2014 /CNW/ - AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including...

2014-05-21 12:49:39

American Chemical Society To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way. Now scientists are solving another side of the disease's problem: identifying the millions more who have the virus but don't know it — and unwittingly pass it on. A report in the ACS journal Analytical Chemistry describes a novel, scrapbook-inspired test that does just that. Xuan Mu, Zhi Zheng...

2014-05-19 23:03:14

Advocacy groups warn that threat of viral hepatitis is “creeping up” on city’s vulnerable populations PHILADELPHIA, Pa. (PRWEB) May 19, 2014 A chorus of voices supporting increased access to viral hepatitis testing for Philadelphia residents echoed through a recent city council meeting, as advocacy groups joined forces to deliver a powerful message. More than 55 members of Hep B United Philadelphia, led by the Hepatitis B Foundation, and the Hepatitis C Allies of Philadelphia...


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related